Ad-RTS-hIL-12: Phase I ongoing

Ziopharm reported 3 patient deaths that were unrelated to treatment in an open-label, U.S. Phase I trial evaluating a single

Read the full 203 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE